1. 设计、合成具有HDAC和Bcl-2双重抑制作用的新型抗肿瘤药物，国家自然科学基金(**), 2014-2017

2．药物化学, 山东省自然科学基金杰出青年基金(JQ201319), 2013-2016

3．以Bcl-2 蛋白抑制剂WL-276 为先导物的新型药物分子设计、合成与生物活性研究，国家自然科学基金(**), 2012-2015

4. 教育部新世纪优秀人才支持计划，2012

五、承担教学工作情况

1.主讲课程：

本科：药物化学、制药工艺学、计算机辅助药物设计实验

研究生：高等药物化学、药物信息学、药物设计学实验

2．主持省级教改课题：

山东省研究生教育创新计划项目，2015年

山东省成人高等教育精品资源共享课, 2014年

3．教材编著：

主编：（1）药物化学（第三版），北京：人民卫生出版社，2013年

全国高等学校医药学成人学历（专科）规划教材

（2）执业药师考前冲刺掌中宝 药物化学，2014年

北京：中国协和医科大学出版社

六、代表性学术成果

1. Hou X, Li R, Li K, Yu X, Sun JP, Fang H*. Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target–ligand interaction-based virtual screening.J. Med. Chem.,2014, 57, 9309-9322.

2. Hou X, Li K, Yu X, Sun JP, Fang H*. Protein flexibility in docking-based virtual screening: discovery of novel lymphoid-specific tyrosine phosphatase inhibitors using multiple crystal structures.J. Chem. Inf. Model.2015, 55, 1973-1983.

3. Chen Y, Su Li, Pan W, Yang X, Fang H*. Enantioselective synthesis of 3,5-disubstituted thiohydantoins and hydantoins.Tetrahedron.2015, 71, 9234- 9239.

4. Hou X, Du J, Liu R, Zhou Y, Li M, Xu W, Fang H*. Enhancing the sensitivity of pharmacophore-based virtual screening by incorporating customized ZBG Features: A case study using histone deacetylase 8.J. Chem. Inf. Model.2015, 55, 861-871.

5. Fu H, Han L, Hou X, Dun Y, Wang L, Gong X, Fang H*. Design, synthesis and biological evaluation of saccharin-based N-hydroxybenzamides as histone deacetylases (HDACs) inhibitors.Bioorg. Med. Chem.2015, 23, 5774-5781.

6. Wan Y, Wu S, Xiao G, Liu T, Hou X, Chen C, Guan P, Yang X, Fang H*. (2015) Design, synthesis and preliminary bioactivity studies of 2-thioxo-4-thiazolidinone derivatives as Bcl-2 inhibitors.Bioorg. Med. Chem.2015, 23, 1994-2003.

7. Fu H, Han L, Hou X, Dun Y, Wang L, Gong X, Fang H. Design, synthesis and biological evaluation of 3-aryl-rhodanine benzoic acids as anti-apoptotic protein Bcl-2 inhibitors.Bioorg. Med. Chem.2015, 25, 5265-5269.

8. Wang L, Hou X, Fu H, Pan X, Xu W, Tang W, Fang H*. Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors.Bioorg. Med. Chem.2015, 23, 4364-4374.

9. Yang X, Su L, Hou X, Ding S, Xu W, Wang B, Fang H*. High-performance liquid chromatographic enantioseparation of 3,5-disubstituted hydantoins analogs and temperature-induced reversals of elution orders on a polysaccharide-based chiral stationary phase.J. Chromatogr. A.2014, 1355, 291-295

10. Han L, Wang L, Hou X, Fu S, Song W, Tang W, Fang H*. Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1- dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.Bioorg.Med. Chem.2014, 22, 1529-1538..

11. Guan P, Wang L, Hou X, Wan Y, Xu W, Tang W, Fang H*. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.Bioorg. Med. Chem.2014, 22, 5766-5775.

12. Wang J, Sun F, Han L, Hou X, Pan X, Liu R, Tang W, Fang H*. Design, synthesis, and preliminary bioactivity studies of substituted purine hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors.Med. Chem. Commun.2015, 5, 1887-1891.

13. Hou X, Du J, Zhang J, Du L, Fang H*, Li M*. How to Improve Docking Accuracy of AutoDock4.2: A Case Study Using Different Electrostatic Potentials.J. Chem. Inf. Model.2013, 53, 188?200.

14. Wang J, Wang Q, Zhang L, Fang H*. Design, Synthesis and Preliminary Biological Evaluation of Purine-2,6-diamine Derivatives as Cyclin-dependent Kinase (CDK) Inhibitors.Chin. J. Chem.2013, 31, 1181-1191.

15. Huang S, Wu S, Jia M, Wang J, Xu W and Fang H*. Alkylboronate Synthesis Based on Transition Metal-Catalyzed Hydroboration.Curr. Org. Syn.2013, 10, 683-696.